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factors were associated with better survival: NC at freezing
(5.5  107/kg) (HR  0.25, p  0.004) and FLU containing
preparative regimen (HR  0.16, p  0.018). In patients re-
ceiving a higher cell dose, 2-y survival was 55% versus 16% for
those receiving a lower dose (p  0.005); it was 67% for those
receiving a FLU containing regimen compared to 25% (p 
0.016) for those receiving other regimens. We conclude that
results of UCBT for FA patients are acceptable and can be
improved by better selection of the CB units and use of FLU in
the preparative regimen.
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THE ROLE OF CD4CD25 T REGULATORY (TREG) CELLS IN ALLOGE-
NEIC BONE MARROW TRANSPLANTATION
Blazar, B.R.1, Panoskaltsis-Mortari, A.1, Levine, B.L.2, June, C.H.2,
Lucas, P.J.3, Gress, R.3, Serody, J.S.4, Taylor, P.A.1, 1. Pediatrics,
Univ. Minn, Minneapolis, MN; 2. Cancer Center, Univ. Penn, Phila-
delphia, PA; 3. NCI, Bethesda, MD; 4. Medicine, Microbiology and
Immunology and the Lineberger Comprehensive Cancer Center, UNC-
Chapel Hill, Chapel Hill, NC.
A subpopulation of CD4 T cells that co-expresses CD25, the
IL-2 receptor alpha chain, without evidence of prior activation, has
been shown to be important in self-tolerance by suppressing au-
toimmune responses. These CD4CD25 Treg cells are present
in rodents at a frequency of 8-12% of CD4 T cells and in humans
at lower frequencies (1-4%). In vitro, Treg cells are potent inhib-
itors of alloresponses. Depletion of either host CD25 cells prior
to BMT or donor CD25 cells in the donor graft inoculum
present markedly accelerated graft-versus-host disease (GVHD)
lethality. Whereas supplementing the donor graft with fresh
CD4CD25 Treg cells delayed GVHD lethality, adding ex vivo
activated and expanded Treg cells virtually abolished GVHD le-
thality. These data are consistent with the fact that activated Treg
cells are more potent suppressors than non-activated cells. In
studies in which CD4 effector T cells could be tracked in the
whole animal, Treg cells were found to suppress effector T cell
expansion or homing to lymphoid organs and GVHD target tis-
sues. Tregs that co-expressed high levels of the lymph node hom-
ing receptor, L-selectin, were far more potent than L-selectin lo
cells suggesting that homing of Tregs to secondary lymphoid
organs is critical to preventing alloresponse initiation in vivo. In
other studies, alloengraftment was markedly increased by the in-
fusion of ex vivo activated and expanded donor Treg cells that
expressed high levels of L-selectin. Such engraftment facilitation
was not dependent upon the capacity of host T cells to receive
TGF
 signals. We conclude that the infusion of ex vivo activated
and expanded CD4CD25 is a highly potent means of inhibiting
GVHD and facilitating alloengraftment. Based upon the known
effects of Tregs on suppressing GVHD, augmenting alloengraft-
ment and immune recovery and preserving graft-versus-leukemia
effects, it is clear that a clinical trial of CD425 merits consid-
eration in the context of allogeneic BMT.
16
IMMUNE RECONSTITUTION FOLLOWING CORD BLOOD CELL TRANS-
PLANTATION
Weinberg, K. Childrens Hospital, Los Angeles, CA.
Immune reconstitution after hematopoietic stem cell transplan-
tation (HSCT) is a fundamental problem that affects the clinical
outcome of transplantation, regardless of the stem cell source.
Delays or defects in immune reconstitution contribute to suscep-
tibility to infections with viruses, fungi, and encapsulated bacteria,
EBV-lymphoproliferative disease, and possibly to relapse. Ulti-
mately, immune reconstitution depends on generation of new T
lymphocytes in the thymus, a process that depends on interactions
of thymocytes with thymic epithelial cells (TEC). Critical for TEC
support of thymopoiesis are the cytokines IL-7 and kit ligand (KL).
Umbilical cord blood cell transplantation (UCBCT) is increasingly
employed because of theoretical and empiric advantages such as
ready availability and decreased risk of graft-versus-host disease
(GVHD). Some of the features of UCBC that make them attractive
as a source of HSC may also contribute to difﬁculties in immune
reconstitution. However, this is very difﬁcult to analyze critically in
clinical HSCT because of the large number of technical differences
in transplant regimens, alloreactivity, and poorly understood vari-
ables such as donor and host variation in lymphopoiesis. One
approach to understanding the outcome of UCBCT is based on
analyzing the differences between the cellular components of
UCBC vs other sources of stem cells. All stem cell sources contain
mixtures of HSC, committed myeloid and lymphoid progenitors,
and mature lymphocytes. Analyses of myeloid recovery have shown
that HSC dose can be limiting, hence recommendations for a
minimum number of phenotypic progenitor cells required for
marrow recovery. Murine data from our laboratory suggests that
thymic recovery may also be related to the dose of infused HSC or
lymphoid progenitors. Although the number of HSC in UCBC
sources may be limiting, the increased proliferative potential of
cord blood HSC could also be advantageous. Besides reduced
numbers of T lymphocytes in UCBC, a major difference between
UCBC and other HSC sources, e.g., adult marrow or PBSC, is the
nature of the mature T lymphocytes present in each product. The
T lymphocytes in UCBC are predominantly naïve T lymphocytes
while adults have mainly memory T lymphocytes. Naïve T lym-
phocytes require a greater amount of antigen to stimulate in vitro,
compared to memory T lymphocytes. The decreased ability to
stimulate naïve T cells may account for reduced alloreactivity in
UCBC, but may also lead to decreased sensitivity to nominal
antigens such as viruses. Thus, USCBC recipients may gain less
protection from the adoptive transfer of mature T lymphocytes
than BMT or PBSCT recipients. In addition, T lymphocytes from
UCBC may have altered immune responses mediated by the ex-
posure to immunomodulators in the placental microcirculation,
e.g., G-CSF. Over the last ﬁve years, various studies have shown
that the maintenance of mature T lymphocyte numbers in the
periphery is mediated by homeostatic proliferation, in which di-
viding cells do not undergo activation or further maturation. The
mechanism of homeostatic proliferation differs between cell types.
Naïve T lymphocytes depend on self-antigen and IL-7 as signals
for homeostatic proliferation. IL-7 therapy is an attractive strategy
for promoting post-transplant thymopoiesis but may be compli-
cated by exacerbation of GVHD. Recent murine experiments sug-
gest that expansion of mature T lymphocytes by IL-7 may have a
paradoxical inhibitory effect on thymopoiesis. Some approaches
for translation of these experimental concepts into empirical stud-
ies in UCBCT will be described.
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INFECTIOUS DISEASE COMPLICATIONS AFTER UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN: IM-
PACT OF STEM CELL SOURCE
Barker, J., Wagner, J.E. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Umbilical cord blood (UCB) is being increasingly used as an
alternative source of hematopoietic stem cells (HSC) for unrelated
donor (URD) transplantation. However, how infection risk after
UCB transplantation (UCBT) compares with that seen after URD
bone marrow (BM) transplantation (BMT) is not known. There-
fore, we conducted a retrospective comparison of serious infectious
complications in the ﬁrst 2 years after HSC transplant in children
transplanted for hematologic malignancy at the University of Min-
nesota. Our hypothesis was that due to HLA disparity, delayed
neutrophil recovery, and the naivety of the neonatal immune sys-
tem, UCBT recipients may be at a higher risk of both early and late
infectious complications compared to recipients of unmanipulated
BM. In this retrospective analysis, there were 136 children (18
years of age) with a hematological malignancy who received cyclo-
phosphamide 120 mg/kg and total body irradiation (TBI 1320-
1375 cGy) followed by the transplantation of unmanipulated bone
marrow (BM, n  52), T cell depleted marrow (TCD, n  24), or
umbilical cord blood (n 60). Overall, the cumulative incidence of
one or more serious infections for the entire period was compara-
ble between groups (BM 81%, TCD 83%, UCB 90%; p  0.12).
Analysis of infection density (episodes of serious infection/1000
patient days) within the time periods days 0-42, 43-100, and 101-
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